
Tuesday, September 19, 2023 4:36:13 PM
Bullish ---- surmising he wrote "like m" meaning "like me" agree ??
Recent AVXL News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/27/2023 09:30:41 PM
- Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Monday’s Wall Street Highlights: Walmart, Disney, Lloyds Banking, Mitsui Financial, HSBC, and more • IH Market News • 11/27/2023 11:29:25 AM
- Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023 • GlobeNewswire Inc. • 11/24/2023 01:00:00 PM
- Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety • GlobeNewswire Inc. • 11/22/2023 01:00:00 PM
- Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA) • GlobeNewswire Inc. • 11/20/2023 01:00:00 PM
- Anavex Life Sciences Appoints Senior VP of Regulatory Affairs • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease • GlobeNewswire Inc. • 10/25/2023 12:00:00 PM
- Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration • GlobeNewswire Inc. • 09/14/2023 11:30:00 AM
- Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board • GlobeNewswire Inc. • 09/12/2023 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:30:53 PM
- Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results • GlobeNewswire Inc. • 08/08/2023 11:30:00 AM
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety • GlobeNewswire Inc. • 08/07/2023 11:30:00 AM
- Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023 • GlobeNewswire Inc. • 08/02/2023 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023 • GlobeNewswire Inc. • 08/01/2023 11:30:00 AM
- Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome • GlobeNewswire Inc. • 06/28/2023 11:30:00 AM
- Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem • GlobeNewswire Inc. • 06/27/2023 11:30:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference • GlobeNewswire Inc. • 06/20/2023 11:30:00 AM
- ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome • GlobeNewswire Inc. • 06/15/2023 11:30:00 AM
- Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ • GlobeNewswire Inc. • 06/12/2023 11:30:00 AM
- Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial • GlobeNewswire Inc. • 06/06/2023 11:30:00 AM
- ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine) • GlobeNewswire Inc. • 06/01/2023 11:30:00 AM
- Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results • GlobeNewswire Inc. • 05/09/2023 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023 • GlobeNewswire Inc. • 05/02/2023 11:30:00 AM
- Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension • GlobeNewswire Inc. • 05/01/2023 11:30:00 AM
FEATURED Major Triumph: Music Licensing, Inc. (OTC:SONG) Secures Coveted Royalty Stakes in Masterpieces by Elton John, Miley Cyrus, Lil Wayne, Lil Nas X, XXXTENTACION, & Halsey • Nov 27, 2023 9:00 AM
Nate's Food Co. Successfully Obtains GACC Registration in China, Paving the Way for Contract Execution on Commodities • NHMD • Nov 28, 2023 8:00 AM
Mass Megawatts Announces LOWEST PRICE GUARANTEE on Solar Project Sales and Further Cost Reductions Using our Patent Pending Technologies • MMMW • Nov 28, 2023 8:00 AM
Branded Legacy Commences Buyback of 1,000,000 Preferred Class D Shares • BLEG • Nov 28, 2023 7:23 AM
Avant Technologies, Inc. Names Technology Industry Veteran Timothy Lantz as New CEO • AVAI • Nov 28, 2023 7:00 AM
Investor Ideas Potcasts: Interview with Kaya Holdings (OTCQB: KAYS) on the Sacred Mushroom Center - Pioneers with Psilocybin and Advocates for Mental Health • KAYS • Nov 28, 2023 7:00 AM